Transcatheter Aortic Valve Replacement and Impact of Subclinical Leaflet Thrombosis in Low-Risk Patients: LRT Trial 4-Year Outcomes
Circulation: Cardiovascular Interventions · 2023-05 · 16 (5)
DOI: 10.1161/circinterventions.122.012655 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2023-05. Verfasst von Ron Waksman und 21 weiteren Autor:innen. Beteiligte Einrichtung: Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC (R.W., S.B., I.B.-D., S.A., J.A.S., C.S., C.Z., H.M.G.-G., L…. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Heart Valve Prosthesis, Stroke. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
The LRT trial (Low-Risk Transcatheter Aortic Valve Replacement [TAVR]) demonstrated the safety and feasibility of TAVR in low-risk patients, with excellent 1- and 2-year outcomes. The objective of the current study is to provide the overall clinical outcomes and the impact of 30-day hypoattenuated leaflet thickening (HALT) on structural valve deterioration at 4 years.
Methods
The prospective, multicenter LRT trial was the first Food and Drug Administration-approved investigational device exemption study to evaluate feasibility and safety of TAVR in low-risk patients with symptomatic severe tricuspid aortic stenosis. Clinical outcomes and valve hemodynamics were documented annually through 4 years.
Results
A total of 200 patients were enrolled, and follow-up was available on 177 patients at 4 years. The rates of all-cause mortality and cardiovascular death were 11.9% and 3.3%, respectively. The stroke rate rose from 0.5% at 30 days to 7.5% at 4 years, and permanent pacemaker implantation rose from 6.5% at 30 days to 11.7% at 4 years. Endocarditis was detected in 2.5% of the cohort, with no new cases reported between 2 and 4 years. Transcatheter heart valve hemodynamics remained excellent post-procedure and were maintained (mean gradient 12.56±5.54 mm Hg and aortic valve area 1.69±0.52 cm 2 ) at 4 years. At 30 days, HALT was observed in 14% of subjects who received a balloon-expandable transcatheter heart valve. There was no difference in valve hemodynamics between patients with and without HALT (mean gradient 14.94±5.01 mm Hg versus 12.3±5.57 mm Hg; P =0.23) at 4 years. The overall rate of structural valve deterioration was 5.8%, and there was no impact of HALT on valve hemodynamics, endocarditis, or stroke at 4 years.
Conclusions
TAVR in low-risk patients with symptomatic severe tricuspid aortic stenosis was found to be safe and durable at 4 years. Structural valve deterioration rates were low irrespective of the type of valve, and the presence of HALT at 30 days did not affect structural valve deterioration, transcatheter valve hemodynamics, and stroke rate at 4 years. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02628899.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC (R.W., S.B., I.B.-D., S.A., J.A.S., C.S., C.Z., H.M.G.-G., L.F.S., T.R.).
- Division of Cardiology, Miriam Hospital, Providence, RI (P.G.).
- Division of Cardiothoracic Surgery, Lifespan Cardiovascular Institute, Providence, RI (A.E.).
- Department of Cardiology, North Shore University Hospital, Manhasset, NY (S.R.W.).
- Department of Cardiology, HCA Virginia Health System, Richmond (R.L.).
- Department of Medicine (P.P.), Stony Brook Hospital, NY. St.
ORCID-Profile: Ron Waksman, Afshin Ehsan, Puja Parikh, Thomas Bilfinger, Maurice Buchbinder, Federico M Asch, Syed Ali, Cheng Zhang, Hector M Garcia-Garcia, Toby Rogers
Zitieren
APA
Waksman, R., Bhogal, S., Gordon, P., Ehsan, A., Wilson, S. R., Levitt, R., Parikh, P., Bilfinger, T., Hanna, N., Buchbinder, M., Asch, F. M., Kim, F. Y., Weissman, G., Ben-Dor, I., Shults, C. C., Ali, S., Sutton, J. A., Shea, C., Zhang, C., …, & Rogers, T. (2023). Transcatheter Aortic Valve Replacement and Impact of Subclinical Leaflet Thrombosis in Low-Risk Patients: LRT Trial 4-Year Outcomes. Circulation: Cardiovascular Interventions, 16(5). https://doi.org/10.1161/circinterventions.122.012655
Vancouver
Waksman R, Bhogal S, Gordon P, Ehsan A, Wilson SR, Levitt R, et al. Transcatheter Aortic Valve Replacement and Impact of Subclinical Leaflet Thrombosis in Low-Risk Patients: LRT Trial 4-Year Outcomes. Circulation: Cardiovascular Interventions. 2023;16(5). doi:10.1161/circinterventions.122.012655
BibTeX
@article{Waksman2023,
author = {Waksman, Ron and Bhogal, Sukhdeep and Gordon, Paul and Ehsan, Afshin and Wilson, Sean R and Levitt, Robert and Parikh, Puja and Bilfinger, Thomas and Hanna, Nicholas and Buchbinder, Maurice and Asch, Federico M and Kim, Francis Y and Weissman, Gaby and Ben-Dor, Itsik and Shults, Christian C and Ali, Syed and Sutton, Joseph A and Shea, Corey and Zhang, Cheng and Garcia-Garcia, Hector M and Satler, Lowell F and Rogers, Toby},
title = {Transcatheter Aortic Valve Replacement and Impact of Subclinical Leaflet Thrombosis in Low-Risk Patients: LRT Trial 4-Year Outcomes},
journal = {Circulation: Cardiovascular Interventions},
year = {2023},
volume = {16},
number = {5},
doi = {10.1161/circinterventions.122.012655}
}
EUVIMED